This technology utilizes AT1 receptor antagonists, particularly Candesartan, to address stress-induced insomnia by targeting the central Ang II system. It works by reducing stress-triggered overexpression of AT1 receptors in the limbic brain regions, such as the bed nucleus of the stria terminalis and the central nucleus of the amygdala. Experimental studies in a soiled cage rat model demonstrated that administration of 1 mg/kg intraperitoneally leads to reduced sleep latency, increased non-REM and REM sleep, maintenance of normal EEG patterns, and decreased overactivity in limbic, arousal, and cortical areas. The use of lower doses compared to those for hypertension further enhances its tolerability.
Description
This approach is differentiated by its mechanistic specificity, selectively modulating stress-related neural pathways rather than broadly depressing central nervous system activity. It preserves natural sleep architecture and minimizes the cognitive impairments and REM suppression typically associated with traditional sedative agents. Additionally, its established FDA-approved safety profile for hypertension allows a potentially dual therapeutic benefit, offering a promising and innovative alternative for patients experiencing both insomnia and elevated blood pressure.
Applications
- Stress-induced insomnia treatment
- Hypertension comorbid insomnia therapy
- Non-sedative sleep aid product
- Combination sleep therapy formulation
Advantages
- Enhances both non-REM and REM sleep, maintaining normal sleep architecture.
- Reduces sleep latency and overall CNS hyperactivity without inducing abnormal EEG patterns.
- Offers a targeted approach with fewer side effects compared to traditional sedative-hypnotics.
-Leverages an already established FDA-approved compound, ensuring a favorable safety profile.
- Provides potential dual benefits for patients with both insomnia and hypertension.
IP Status
https://patents.google.com/patent/US11439624B2
